Literature DB >> 11870114

Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men.

Peter Y Liu1, Val J Gebski, Leo Turner, Ann J Conway, Susan M Wishart, David J Handelsman.   

Abstract

BACKGROUND: Predictors of fertility or spermatogenesis during gonadotrophin therapy of gonadotrophin-deficient men remain poorly defined. METHODS AND
RESULTS: In order to evaluate potential predictors, this study evaluated 29 consecutive gonadotrophin-deficient men all desiring paternity who received 43 courses of therapy in one centre between 1982 and 1998. The Kaplan-Meier survival analysis estimates of median (SE) time to a sperm concentration of >0, >5 and >20 x 10(6)/ml were 5.5 (1.1), 12.4 (2.3) and 29.1 (1.9) months respectively. Conception occurred in 22/43 cycles (with eight men achieving two pregnancies) with a median (SE) Kaplan-Meier estimate of 20.5 (4.7) months. The median sperm concentration at conception was 5.0 (SE 2.0; range 0.0-59.5) x 10(6)/ml. Multivariate correlated Cox proportional hazards models predicting these same sperm thresholds and conception were developed by forward stepwise variable selection with verification of the model by backward stepping. Larger testicular volume, prior gonadotrophin therapy, completion of puberty, older age, the absence of adverse fertility factors and the absence of multiple pituitary hormone deficiency predicted a favourable response. Multivariate modelling suggests that the two most important predictors of sperm output are testicular volume and pubertal status. The most important potentially modifiable predictor was prior gonadotrophin therapy. The efficacy of recombinant and urinary FSH were similar. Prior androgen therapy and partner's age did not appear to be significant.
CONCLUSIONS: Since prolonged treatment may be required to induce spermatogenesis, attention to these predictors may allow appropriate early use of advanced reproductive technologies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11870114     DOI: 10.1093/humrep/17.3.625

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  18 in total

1.  Whither must spermatozoa wander? The future of laboratory seminology.

Authors:  R John Aitken
Journal:  Asian J Androl       Date:  2010-01       Impact factor: 3.285

Review 2.  Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism.

Authors:  Claire Bouvattier; Luigi Maione; Jérôme Bouligand; Catherine Dodé; Anne Guiochon-Mantel; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

3.  Efficacy of recombinant human follicle stimulating hormone at low doses in inducing spermatogenesis and fertility in hypogonadotropic hypogonadism.

Authors:  A A Sinisi; D Esposito; G Bellastella; L Maione; V Palumbo; L Gandini; F Lombardo; A De Bellis; A Lenzi; A Bellastella
Journal:  J Endocrinol Invest       Date:  2010-04-30       Impact factor: 4.256

Review 4.  Medical therapy for spermatogenic failure.

Authors:  Ranjith Ramasamy; Peter J Stahl; Peter N Schlegel
Journal:  Asian J Androl       Date:  2011-12-19       Impact factor: 3.285

Review 5.  Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism.

Authors:  A Lenzi; G Balercia; A Bellastella; A Colao; A Fabbri; C Foresta; M Galdiero; L Gandini; C Krausz; G Lombardi; F Lombardo; M Maggi; A Radicioni; R Selice; A A Sinisi; G Forti
Journal:  J Endocrinol Invest       Date:  2009-12-01       Impact factor: 4.256

6.  Outcome of gonadotropin therapy for male infertility due to hypogonadotrophic hypogonadism.

Authors:  Rafif Farhat; Fatma Al-zidjali; Ali S Alzahrani
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

7.  Recombinant follitropin alfa/lutropin alfa in fertility treatment.

Authors:  Ahmed Gibreel; Siladitya Bhattacharya
Journal:  Biologics       Date:  2010-02-04

Review 8.  Gonadotropins in doping: pharmacological basis and detection of illicit use.

Authors:  U-H Stenman; K Hotakainen; H Alfthan
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

9.  A successful conception by a shift from human menopausal gonadotropin therapy to therapy with recombinant human follicular-stimulating hormone for the treatment of male hypogonadotropic hypogonadism.

Authors:  Kohei Koyama; Hiroshi Masuda; Teruo Inamoto; Naoki Segawa; Haruhito Azuma; Yoji Katsuoka
Journal:  Reprod Med Biol       Date:  2009-10-06

10.  Prior testosterone replacement therapy may impact spermatogenic response to combined gonadotropin therapy in severe congenital hypogonadotropic hypogonadism.

Authors:  Ravikumar Shah; Virendra Patil; Vijaya Sarathi; Anurag R Lila; Margaret Zacharin; Brijesh Krishnappa; Manjeetkaur Sehemby; Sanjeet Kumar Jaiswal; Pratap L Jadhav; Swati Ramteke-Jadhav; Nalini Shah; Tushar Bandgar
Journal:  Pituitary       Date:  2020-11-23       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.